Bayer Pharma Aktiengesellschaft

Boehringer Ingelheim International Gmbh

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

The Broad Institute, Inc.

Dana-farber-cancer Institute Inc.

Bayer Healthcare Aktiengesellschaft

Adrian Tersteegen

Stefan Heitmeier

Susanne Röhrig

Alexander Hillisch

Karl-Heinz Schlemmer

Martin Hendrix

Martina Schäfer

Martina Victoria Schmidt

Christoph Gerdes

Henrik Teller

Dieter Lang

Anja Buchmüller

Marja Van Kampen

Dagmar Karthaus

Lars Bärfacker

Christina Erb

Heike Heckroth

Jens Ackerstaff

Alexandros Vakalopoulos

Hartmut Schirok

Eloisa Jimenez Nunez

Johannes-Peter Stasch

Frank Wunder

Markus Follmann

Gorden Redlich

Mark Jean Gnoth

Frank-Thorsten Hafner

Dmitry Zubov

Franz-Josef Van Der Staay

Ulrich Rester

Philip Lienau

Alexander Straub

Katja Zimmermann

Hanna Tinel

Heinrich Meier

Raimund Kast

Chantal Fürstner

Jürgen Klar

Jens Schamberger

Detlev Sülzle

Timothy A Lewis

Martin Lange

Andreas Wilmen

Nils Burkhardt

Niels Svenstrup

Heidi Greulich

Stefan Nikolaus Gradl

Stephan Siegel

Manuel Ellermann

Kirsten Börngen

Xiaoyun Wu

Charlotte Christine Kopitz

Tom Kinzel

Julia Straβburger

Nils Griebenow

Walter Hübsch

Matthew Meyerson

Frank-Gerhard Böβ

Marcus Bauser

Mario Lobell

Swen Allerheiligen

Michael Gerisch

Alex Burgin

Volkhart Min-Jian Li

Daniel Meibom

Tobias Marquardt

Holger Paulsen

Kersten Matthias Gericke

Damian Brockschnieder

Dirk Heimbach

Arno Friedl

Alexey Gromov

Gerhard Siemeister

Ulf Bömer

Jörg Keldenich

Bernd Riedl

Niels Lindner

Paul Naab

Ingo Flamme

Hartmut Beck

Ulrich Ebert

Jens Hoffmann

Simon Holton

Thomas Neubauer

Frank Mauler

Donald Bierer

Kirstin Petersen

Dietmar Flubacher

Jens-Kerim Ergüden

Carsten Terjung

Lutz Lehmann

Georges Von Degenfeld

Karen Engel

Reinhard Jork

Joachim Krüger

Maria Niewöhner

Maria Niewöhner, Legal Representative

Frank Süssmeier

Herbert Himmel

Dagmar Schauss

The present invention includes name compounds of general formula (I): (I) in which R, R, Rand Rare as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.

1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Dihydrooxadiazinones

The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Substituted S-alaninate derivatives

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

Substituted oxopyridine derivative

The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

MASP inhibitory compounds and uses thereof

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. 

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives

The invention relates to substituted oxopyridine derivatives of formula (I) and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders. 

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.

Bicyclically substituted uracils and the use thereof

Substituted oxopyridine derivatives and use thereof cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives

Growing community of inventors

Wuppertal, Germany

Adrian Tersteegen